BAJAJ BROKING

Notification close image
No new Notification messages
card image
Anondita Medicare IPO is Open!
Apply for the Anondita Medicare IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

0

511509

VIVOBIOT

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

VIVO BIO TECH LTD. Share Price Update

As of the latest trading session, VIVO BIO TECH LTD. share price is currently at ₹ 38.45, which is up by ₹ 0.13 from its previous closing. Today, the stock has fluctuated between ₹ 37.12 and ₹ 39.46. Over the past year, VIVO BIO TECH LTD. has achieved a return of 7.54 %. In the last month alone, the return has been 14.96 %. Read More...

Investment Returns

Over 1 Month 14.96% Over 3 Months 6.46% Over 6 Months 0.65% Over 1 Year 7.54%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

VIVO BIO TECH LTD. fundamentals


  • Market cap (Cr)

  • P/E Ratio (TTM)

  • Beta

  • Book Value / share

  • Return on equity

    %

  • EPS (TTM)

  • Dividend yield

    %

  • Net profit/quarter (Cr)

info icon alternate text
  • Market cap (Cr)

    76.20

  • P/E Ratio (TTM)

    8.75

  • Beta

    0.53

  • Book Value / share

    41.83

  • Return on equity

    4.74%

  • EPS (TTM)

    4.38

  • Dividend yield

    %

  • Net profit/quarter (Cr)

    1.37

info icon alternate text

VIVO BIO TECH LTD. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars JUN 2025 (Values in Cr)
Revenue 12.42
Operating Expense 11.04
Net Profit 1.37
Net Profit Margin (%) 11.03
Earnings Per Share (EPS) 0.76
EBITDA 5.66
Effective Tax Rate (%) 9.21
Particulars MAR 2025 (Values in Cr)
Revenue 12.29
Operating Expense 11.08
Net Profit 1.19
Net Profit Margin (%) 9.68
Earnings Per Share (EPS) 0.78
EBITDA 5.29
Effective Tax Rate (%) 13.23
Particulars DEC 2024 (Values in Cr)
Revenue 12.21
Operating Expense 10.69
Net Profit 0.89
Net Profit Margin (%) 7.28
Earnings Per Share (EPS) 0.60
EBITDA 5.63
Effective Tax Rate (%) 41.55
Particulars SEP 2024 (Values in Cr)
Revenue 12.04
Operating Expense 10.72
Net Profit 5.31
Net Profit Margin (%) 44.10
Earnings Per Share (EPS) 3.56
EBITDA 10.30
Effective Tax Rate (%) 10.58
Particulars JUN 2024 (Values in Cr)
Revenue 10.13
Operating Expense 9.91
Net Profit 0.18
Net Profit Margin (%) 1.77
Earnings Per Share (EPS) 0.12
EBITDA 4.38
Effective Tax Rate (%) 26.08
Particulars MAR 2025 (Values in Cr)
Revenue 46.67
Operating Expense 42.39
Net Profit 7.57
Net Profit Margin (%) 16.22
Earnings Per Share (EPS) 4.95
EBITDA 25.59
Effective Tax Rate (%) 16.62
Particulars MAR 2024 (Values in Cr)
Revenue 44.88
Operating Expense 40.87
Net Profit 2.52
Net Profit Margin (%) 5.61
Earnings Per Share (EPS) 1.69
EBITDA 21.11
Effective Tax Rate (%) 37.77
Particulars MAR 2023 (Values in Cr)
Revenue 51.62
Operating Expense 47.05
Net Profit 2.63
Net Profit Margin (%) 5.09
Earnings Per Share (EPS) 1.77
EBITDA 21.53
Effective Tax Rate (%) 42.73
Particulars MAR 2022 (Values in Cr)
Revenue 51.39
Operating Expense 47.01
Net Profit 2.20
Net Profit Margin (%) 4.28
Earnings Per Share (EPS) 1.56
EBITDA 15.90
Effective Tax Rate (%) 50.78
Particulars MAR 2021 (Values in Cr)
Revenue 51.78
Operating Expense 43.23
Net Profit 5.68
Net Profit Margin (%) 10.96
Earnings Per Share (EPS) 4.24
EBITDA 17.74
Effective Tax Rate (%) 34.10
Particulars MAR 2024 (Values in Cr)
Book Value / Share 36.50
ROE % 4.76
ROCE % 9.88
Total Debt to Total Equity 1.27
EBITDA Margin 46.86
Particulars MAR 2023 (Values in Cr)
Book Value / Share 34.81
ROE % 5.35
ROCE % 10.97
Total Debt to Total Equity 1.31
EBITDA Margin 41.89
Particulars MAR 2022 (Values in Cr)
Book Value / Share 32.56
ROE % 4.91
ROCE % 9.25
Total Debt to Total Equity 1.10
EBITDA Margin 31.50
Particulars MAR 2021 (Values in Cr)
Book Value / Share 30.63
ROE % 15.03
ROCE % 18.65
Total Debt to Total Equity 0.73
EBITDA Margin 34.53
Particulars MAR 2020 (Values in Cr)
Book Value / Share 25.62
ROE % 14.73
ROCE % 13.72
Total Debt to Total Equity 0.76
EBITDA Margin 22.62
Particulars MAR 2024 (Values in Cr)
Book Value / Share 36.50
ROE % 4.74
ROCE % 10.06
Total Debt to Total Equity 1.23
EBITDA Margin 47.46
Particulars MAR 2023 (Values in Cr)
Book Value / Share 34.81
ROE % 5.31
ROCE % 11.16
Total Debt to Total Equity 1.27
EBITDA Margin 42.35
Particulars MAR 2022 (Values in Cr)
Book Value / Share 32.57
ROE % 4.91
ROCE % 9.47
Total Debt to Total Equity 1.05
EBITDA Margin 31.48
Particulars MAR 2021 (Values in Cr)
Book Value / Share 30.64
ROE % 15.03
ROCE % 19.31
Total Debt to Total Equity 0.67
EBITDA Margin 34.53
Particulars MAR 2020 (Values in Cr)
Book Value / Share 25.63
ROE % 14.72
ROCE % 14.02
Total Debt to Total Equity 0.73
EBITDA Margin 22.64
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1.38
Total Assets 137.13
Total Liabilities 137.13
Total Equity 54.39
Share Outstanding 14903520
Price to Book Ratio 1.17
Return on Assets (%) 1.84
Return on Capital (%) 1.98
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1.37
Total Assets 123.03
Total Liabilities 123.03
Total Equity 51.87
Share Outstanding 14903520
Price to Book Ratio 0.55
Return on Assets (%) 2.15
Return on Capital (%) 2.32
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1.71
Total Assets 122.48
Total Liabilities 122.48
Total Equity 47.12
Share Outstanding 14263520
Price to Book Ratio 1.22
Return on Assets (%) 1.79
Return on Capital (%) 1.92
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.16
Total Assets 79.52
Total Liabilities 79.52
Total Equity 42.52
Share Outstanding 13419520
Price to Book Ratio 1.56
Return on Assets (%) 7.14
Return on Capital (%) 7.73
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1.02
Total Assets 63.68
Total Liabilities 63.68
Total Equity 33.02
Share Outstanding 12887520
Price to Book Ratio 0.76
Return on Assets (%) 6.97
Return on Capital (%) 7.74
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1.31
Total Assets 134.80
Total Liabilities 134.80
Total Equity 54.39
Share Outstanding 14903520
Price to Book Ratio 1.17
Return on Assets (%) 1.87
Return on Capital (%) 2.01
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.99
Total Assets 120.80
Total Liabilities 120.80
Total Equity 51.87
Share Outstanding 14903520
Price to Book Ratio 0.55
Return on Assets (%) 2.18
Return on Capital (%) 2.35
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1.46
Total Assets 120.29
Total Liabilities 120.29
Total Equity 47.14
Share Outstanding 14263520
Price to Book Ratio 1.22
Return on Assets (%) 1.83
Return on Capital (%) 1.96
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.09
Total Assets 77.30
Total Liabilities 77.30
Total Equity 42.54
Share Outstanding 13419520
Price to Book Ratio 1.56
Return on Assets (%) 7.35
Return on Capital (%) 7.98
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 0.99
Total Assets 61.42
Total Liabilities 61.42
Total Equity 33.03
Share Outstanding 12887520
Price to Book Ratio 0.76
Return on Assets (%) 7.23
Return on Capital (%) 8.06
Particulars MAR 2024 (Values in Cr)
Net Income 4.06
Cash from Operations 18.58
Cash from Investing -7.95
Cash from Financing -7.55
Net change in Cash 0.01
Free Cash Flow 26.53
Particulars MAR 2023 (Values in Cr)
Net Income 4.62
Cash from Operations 18.17
Cash from Investing -3.99
Cash from Financing -11.17
Net change in Cash -0.33
Free Cash Flow 22.17
Particulars MAR 2022 (Values in Cr)
Net Income 4.47
Cash from Operations 20.09
Cash from Investing -51.11
Cash from Financing 35.01
Net change in Cash 0.54
Free Cash Flow 71.20
Particulars MAR 2021 (Values in Cr)
Net Income 8.61
Cash from Operations 20.64
Cash from Investing -22.82
Cash from Financing 8.78
Net change in Cash 0.13
Free Cash Flow 43.46
Particulars MAR 2020 (Values in Cr)
Net Income 4.25
Cash from Operations 11.51
Cash from Investing -10.23
Cash from Financing 2.09
Net change in Cash 0.46
Free Cash Flow 21.75
Particulars MAR 2024 (Values in Cr)
Net Income 4.05
Cash from Operations 18.88
Cash from Investing -7.95
Cash from Financing -7.55
Net change in Cash 0.32
Free Cash Flow 26.83
Particulars MAR 2023 (Values in Cr)
Net Income 4.60
Cash from Operations 18.06
Cash from Investing -3.99
Cash from Financing -11.20
Net change in Cash -0.47
Free Cash Flow 22.06
Particulars MAR 2022 (Values in Cr)
Net Income 4.47
Cash from Operations 19.88
Cash from Investing -51.10
Cash from Financing 35.04
Net change in Cash 0.36
Free Cash Flow 70.99
Particulars MAR 2021 (Values in Cr)
Net Income 8.62
Cash from Operations 20.56
Cash from Investing -22.82
Cash from Financing 8.83
Net change in Cash 0.10
Free Cash Flow 43.38
Particulars MAR 2020 (Values in Cr)
Net Income 4.25
Cash from Operations 10.62
Cash from Investing -7.07
Cash from Financing -0.17
Net change in Cash 0.46
Free Cash Flow 17.69
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 34.22 13.97 1.87 262.24 30.00 / 69.75
BLISS GVS PHARMA LTD 166.55 16.47 1.67 1757.06 105.05 / 190.65
CIPLA LTD 1545.85 23.16 4.00 124866.66 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 342.40 9.64 2.77 1007.72 219.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 34.22 18.60 5.40 262.24 30.00 / 69.75
AMRUTAJAN HEALTH LTD 722.05 38.28 6.39 2087.49 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8450.65 99.90 27.42 21126.63 6222.35 / 10653.05
BLISS GVS PHARMA LTD 166.55 24.90 1.65 1757.06 105.05 / 190.65

VIVO BIO TECH LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
38.08 -0.62 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 38.30
  • 26 Days 36.30
  • 10 Days 37.30
  • 50 Days 36.40
  • 12 Days 37.10
  • 100 Days 37.10
  • 20 Days 36.50
  • 200 Days 37.80
40.49 PIVOT

First Support

37.69

First Resistance

43.99

Second Support

34.19

Second Resistance

46.79

Third Support

31.39

Third Resistance

50.29

RSI

69.86

ADX

17.91

MACD

0.69

Williams % R

-18.76

Commodity Channel Index (CCI)

215.62

Date

2025-08-20

Week

54783.00

Same Day

163776.00

Month

40905.00

1 Year

0.54

3 Year

0.45

Over 1 Month

14.96%

down

Over 1 Year

7.54%

down

Over 3 Months

6.46%

down

Over 3 Years

9.34%

down

Over 6 Months

0.65%

down

Over 5 Years

-5.53%

down

Transparent Pricing, 360° Services

Choose a plan that best suits your goals & needs.

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : 2500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Expert Stock Research tick Experienced Dealer Support

VIVO BIO TECH LTD. shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Name Shares Category

News

Left Arrow
Right Arrow

VIVO BIO TECH LTD. corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

VIVO BIO TECH LTD. Share Price

Vivo Bio Tech Limited, established in February, 1987 is a full service CRO offering drug development & discovery services to pharmaceutical & biotech companies world-wide in accordance with OECD, AAALAC & IND guidelines. The company offers services in the areas of In vitro, In vivo, toxicity studies, pharmacological investigations, pharmacokinetics & toxicokinetic studies etc. Their experienced & talented scientists offer advice on defining drug development paths tailored to specific molecules.

The Company stands as a premier and primary provider of SPF lab animals in India. It holds the distinction of being the largest breeder and distributor of rodent models, in addition to offering custom rodent models and stem cell products through Cyagen Biosciences. The Company serves as an authorized distributor of lab animal diets from Special Diets Services (UK) in India. It pioneered the commercial distribution of SPF guinea pigs, sourcing breeders from Elm Hill Labs (USA). Employing topquality SPF breed in their in-house lab animals, the Company upholds excellence in all pre clinical studies. Their comprehensive services span a wide array of preclinical toxicology disciplines, encompassing In-vitro and In-vivo studies, analytical chemistry studies, bioanalytical studies, and physico-chemical studies. Moreover, the Company boasts supplementary satellite facilities situated in Pregnapur Village, Siddipet District, Hyderabad, Telangana.

The Biologic Research Services group at Vivo Bio Tech offers a complete line of protein services, including gene synthesis, cloning, expression and purification of re-combinant proteins and monoclonal antibodies. In-vitro Services offers solutions for pharmacologic, toxicological & bio analytical investigations in drug discovery & development. Critical investigations like bacterial reverse mutation assays, chromosomal aberration, and micronucleus are specialty services by the scientists.

The In-vivo Services group at Vivo Bio Tech provides both non-regulatory and regulatory IND enabling pre clinical development services. We are capable of screening & evaluating molecules for various pharmacological & therapeutic properties. Specifically for oncology, scientists provide design & development of xenograft models for evaluation of anti-cancer agents. Further, scientists customize in-vivo DMPK studies to help drug candidate in both rodent and non-rodent animal models.

Vivo Bio has partnered with Taconic for sourcing foundation and expansion colonies of the animal models and have started in-house breeding of Specific Pathogen Free rodents.

The Company partnered Cyagen Biosciences to access genomic technologies in 2016. It commenced breeding and distribution of SPF guinea pigs in 2017. The Company acquired 100% shareholding in M/s. Donakanti Consulting Services Private Ltd on 17 April, 2019. It received ISO 9001:2015 Certification for Quality Management System. The Company completed NGCMA - OECD GLP Surveillance and Scope Extension with the introduction of inhalational studies in 2019.

The Company transformed from an animal breeding and distributing company into a full service CRO with interest in In-vitro, In-vivo, EcoTox, Analytical, Bio -Analytical and Physchem, ADME and PK-PD studies in 2021-22.

Parent organization Indian Private
NSE symbol [-]
Founded 1987
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Vivo Bio Tech Ltd?

Answer Field

Vivo Bio Tech Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 38.08 as on Aug 22 2025 03:30 PM.

What is the Market Cap of Vivo Bio Tech Ltd Share?

Answer Field

The market cap of Vivo Bio Tech Ltd for NSE ₹ 0.00 & for BSE ₹ 76.20 as on Aug 22 2025 03:30 PM.

What is the 52 Week High and Low of Vivo Bio Tech Ltd?

Answer Field

The 52 Week High and Low of Vivo Bio Tech Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 56.90 and ₹ 31.20.

What is 1 year return for Vivo Bio Tech Ltd?

Answer Field

The 1 year returns on the stock has been -0.62%.

What is the P/E Ratio of Vivo Bio Tech Ltd Share?

Answer Field

As on Aug 22 2025 03:30 PM the price-to-earnings (PE) ratio for Vivo Bio Tech Ltd share is 8.75.

What is the PB ratio of Vivo Bio Tech Ltd Share?

Answer Field

As on Aug 22 2025 03:30 PM, the price-to-book (PB) ratio for Vivo Bio Tech Ltd share is 41.83.

How to Buy Vivo Bio Tech Ltd Share?

Answer Field

You can trade in Vivo Bio Tech Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Vivo Bio Tech Ltd Share on Bajaj Broking App?

Answer Field

To buy Vivo Bio Tech Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Vivo Bio Tech Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

close-image

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
close-image

Get Free Demat Account*

+91